Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy

Neoplasma

Volumn 54, Issue 3, 2007, Pages 181-188

  Mladosievicova, B ^a   Carter, A ^b   Kristova, V ^c  

^a Bratislava   (Slovakia)

^b University at Maryland   (United States)

^c Faculty of Natural Sciences   (Slovakia)

Author keywords

Anticancer therapy; Efficacy; Genetic variability; Toxicity

Indexed keywords

5 FLUOROURIDINE MONOPHOSPHATE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 THIOURIC ACID; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOPHOSPHAMIDE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; DOXORUBICIN IRON; DOXORUBICINOL; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FLUOROURACIL; GLUCOCORTICOID; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TIOGUANINE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; XANTHINE OXIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE TOXICITY; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CHILDHOOD CANCER; CHRONIC TOXICITY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ETHNIC DIFFERENCE; EXON; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER TOXICITY; NEOPLASM; NEUROTOXICITY; NONHUMAN; OSTEOPENIA; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; PREDICTION; PREDICTOR VARIABLE; REVIEW; TREATMENT RESPONSE; ANIMAL; DRUG SCREENING; GENETICS; MUTAGEN TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MUTAGENICITY TESTS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 34347216743     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. EVANS WE. Clinical pharmacology of childhood ALL: Is the same dose optimal for everyone? Med Ped Oncol 1999; 33: 191.
2. GOETZ MP, AMES MM, WEINSHILBOUM RM. Primer on medical genomics Part XII. Mayo Clin Proc 2004; 79: 376-384
3. DALTON WS, FRIEND SH. Cancer biomarkers - an invitation to the table. Science 2006; 312: 1165-1168.
4. LEHMAN NL. Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 2002; 11: 1775-1787. (Pubitemid 35469921)
5. CIERNIKOVA S, TOMKA M, KOVAC M, STEVURKOVA V, ZAJAC V. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 2006; 53: 97-102.
6. MAITLAND ML, VASISHT K, RATAIN MJ. TP MT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006 Aug; 27: 432-437.
7. GSAPARINI G, LONGO R, TORINO F, BARONE C, TOFFOLI G. Tailored therapy of colorectal cancer: results, challenges and future directions. Cancer J 2005; 11: 175-188. (Pubitemid 44698804)
8. BOMGAARS L, McLEOD HL. Pharmacogenetics and pediatric cancer. Cancer J 2005 Jul-Aug; 11: 314-323.
9. CHEOK MH, EVANS WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nature Rev Cancer 2006; 6: 117-127.
10. JAIN KK. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 2005; 6: 1463-1476. (Pubitemid 41131687)
11. KISHI S, GRIENER J, CHENG CH et al. Homocystein, pharmacogenetics and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084-3089.
12. SHARMA A, MISHRA A, DAS BC, SARDANA S, SHARMA JK. Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. Neoplasma 2006; 53: 309-315. (Pubitemid 44105936)
13. LEE W, LOCKHART AC, KIM RB, ROTHENBERG ML. Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development. Oncologist 2005; 10: 104-111.
14. MARSH S, McLEOD HL. Cancer pharmacogenetics. Br J Cancer 2004, 90: 8-11.
15. KRYNETSKI EY, EVANS WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998; 63: 11-16.
16. PETROS WP, EVANS WE. Pharmacogenomics in cancer therapy: is host genome variability important ? Trends Pharmacol Sci 2004; 25: 457-464.
17. WAWRUCH M, BOZEKOVA L, KRCMERY S, KRISKA M. Risks of antibiotic treatment. Bratisl Lek Listy 2002; 103: 270-275.
18. WAWRUCH M, BOŽEKOVÁ L, MAGULOVÁ L, DOSTÁLOVÁ D, SLÁDEKOVÁ J et al. Interactions of antimycotics in dermatology. Čes-slov Derm 2004; 79: 7-12.
19. WEBER P, KRIŠKA M, MELUZÍNOVÁ H, DÍTĚTOVÁ K, WAWRUCH M. Polypharmacotherapy in clinical gerontology. Čas Lék Čes 2004; 143: 547-551 (in Czech).
20. WAWRUCH M, ZIKAVSKA M, WSOLOVA L, JEZOVA D, FIALOVA D et al. Perception of potentially inappropriate medication in elderly patients by Slovak physicians. Pharmacoepidemiol Drug Saf 2006; 15: (in press).
21. NUSSBAUM RL, McINNES RR, WILLARD HF. Thompson & Thompson Genetics in Medicine. W.B. Saunders, Philadelphia 6th edition 2001, 444 pp.
22. ULRICH CM, ROBIEN K, McLEOD HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912-920.
23. IQBAL S, LENZ HJ. Targeted therapy and pharmacogenetic programs. Cancer 2003; 97: 2076-2078.
24. NAGASUBRAMANIAN R, INNOCENTI F, RATAIN MJ. Pharmacogenetics in cancer treatment. Ann Rev Med 2003; 54: 437-452.
25. EFFERTH T, VOLM M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005; 107: 155-176.
26. INNOCENTI I, IYER L, RATAIN MJ. Pharmacogenomics of chemotherapeutic agents in cancer treatment. In: Licinio J, Ma-Li Wong. Pharmacogenomics. The Search for Individualized Therapies. Weinheim: Wiley-VCH Verlag 2002a: 283-303.
27. MARTIN YN, SALAVAGGIONE OE, ECKLOFF BW, WIEBEN ED, SCHAID DJ, WEINSHILBOUM RM. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics 2006 Apr;16: 265-277.
28. MLADOSIEVICOVA B, FOLTINOVA A, WAWRUCH M. Genetic tests in prediction of efficacy and toxicity of chemotherapy in cancer patients Vnitř Lék 2005; 51: 560-565 (in Slovak).
29. OMURA K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitors fluoropyrimidines. Int J Clin Oncol 2003; 8: 132-138.
30. PULLARKAT ST, STOEHLMACHER J, GHADERI V, XIONG IQ, INQLES SA et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1: 65-70.
31. MATHIJSSEN RH, MARSH S, KARLSSON MO, XIE R, BAKER SD et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246-3253.
32. [32) MAITLAND ML, DIRIENZO A, RATAIN MJ. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol 2006; 24: 2151-2157.
33. RELLING MV, HANCOCK ML, RIVERA GK, SANDLUND JT, RIBEIRO R et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999a; 91: 2001-2008.
34. RELLING MV, RUBNITZ JE, RIVERA GK, BOYETT JM, HANCOCK ML et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999b; 354: 34-39.
35. RELLING MV, DERVIEUX T. Pharmacogenetics and cancer therapy: Nat Rev Cancer 2001; 1: 99-108.
36. RELLING MV, PUI CH, CHENG CH. Thiopurine methyl-transferase in acute lymphoblastic leukemia. Blood 2006; 107: 843-844. (Pubitemid 43076417)
37. KRYNETSKI EY, SCHUETZ JD, GALPIN AJ et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci 1995; 92: 949-953.
38. DAVIES SM, BHATIA S, ROSS JA et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002; 100: 67-71. (Pubitemid 35177430)
39. EVANS WE, RELLING MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 1999; 5439: 487-491.
40. SCHAEFFELER E, EICHELBAUM M, REINISCH W, ZANGER UM, SCHWAB M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat 2006 Sep; 27(9): 976.
41. KRYNETSKI EY, EVANS WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136-146.
42. KRYNETSKI EY, EVANS WE.Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22, 2003; 47: 7403-7413.
43. MARSHALL E. Preventing toxicity with a gene test. Science 2003; 302(5645): 588-590
44. McLEOD HL, KRYNETSKI EY, RELLING MV, EVANS WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood lymphoblastic leukemia. Leukemia 2000; 14: 567-572.
45. McLEOD HL, SIVA C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
46. KHAM SK, TAN PL, TAY AH, HENG CK, YEOH AF et al. Thiopurine methyltransferase polymorphism in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2002; 24: 353-359.
47. DeMICHELE A, APLENC R, BOTBYL J, COLLIGAN T, WRAY L, KLEIN-CABRAL M, FOULKES A, GIMOTTY P, GLICK J, WEBER B, STADTMAUER E, REBBECK TR. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 2005 Aug 20; 23: 5552-5559.
48. STOEHLMACHER J, PARK DJ, ZHANG W et al. Association between glutathione s-transferase P1, T1, and M1 genetic polymorphism and surival of patients with metastatic colorectal caneer. J Natl Cancer Inst 2002 Jun; 94(12): 936-942.
49. DAVIES SM, ROBISON LL, BUCKLEY JD et al. Glutathion-S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19: 1279-1287. (Pubitemid 32202531)
50. ELLIOTT P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33, Suppl 8: 2-7.
51. MLADOSIEVIČOVÁ B, FOLTINOVÁ A, PETRÁŠ OVÁ H, HULÍN I. Late effects of anthracycline therapy in childhood on signal-averaged ECG parameters. Int J Mol Med 2000 Apr; 5: 411-414.
52. MINOTTI G, CAIRO G, MONTI E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 1999; 13: 199-212.
53. APLENC R, BLANCO J, LEISENRING W et al. Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: A Report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I., Vol 24 (June 20 Suppl): 9004.
54. WASTERNACK C. Degradation of pyrimidines and pyrimidine analogs - pathways and mutual influences. Pharmacol Ther 1980; 8: 629-652.
55. HEGGIE GD, SOMMADOSSI JP, CROSS DS, HUSTLER WJ, DIASIO RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-2206. (Pubitemid 17074634)
56. RAIDA M, FRIEDRICH A, BORRIS M, NIEDERWIESER D, BEHNKE D, KLICHE KO et al. Final results of a prospective multicenter study on the prevalence and genotype/phenotype correlation of the dihydropyrimidine dehydrogenase (DPD) gene exon-14 skipping mutation in patients treated with 5-fluorouracil (5-FU) chemotherapy. J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I., Vol 24 (18S) (June 20 Supplement), 2006: 3076
57. REED HA, EZZELDIN HH, MATTISON LK, DIASI RB. Molecular basis of altered uracil catabolism in individuals with 5-FU toxicity and normal DPD enzyme activity. J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I., Vol 24 (18S) (June 20 Supplement), 2006: 3070.
58. NAGAR S, REMMEL RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006; 25: 1659-1672.
59. RIVORY L P, BOWLES M R, ROBERT J, POND S M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol 1996; 52: 1103-1111.
60. BOSMA PJ, CHOWDHURY JR, BAKKER C, GANTLA S, DE BOER A et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175.
61. BEUTLER E, GELBART T, DEMINA A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-8174.
62. INNOCENTI F, GRIMSLEY D, DAS S, RAMIREZ J, CHENG C et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002b; 12: 725-733.
63. SEYMOUR MT, BRAUN MS, RICHMAN, SD et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer (FOCUS). J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I., Vol 24 (18S) (June 20 Supplement), 2006: 2022.
64. GUSELLA M, BOLZONELLA C, BERTOLASO L et al. TYMS polymorphism analysis prediction of bolus 5-fluorouracil toxicity. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I., Vol 24 (18S) (June 20 Suppl), 2006: 13022.
65. CHIUSOLO P, REDDICONTO G, CASORELLI I, LAURENTI L, SORA F et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13: 1915-1918.
66. BORST P, SCHINKEL AH, SMIT JJ, WAGENAAR E, VAN DEEMTER L et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993; 60: 289-299.
67. SCHINKEL AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170.
68. LEONESSA F, CLARKE R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003; 10: 43-73. (Pubitemid 36457239)
69. MAHADEVAN D, LIST AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104: 1940-1951.
70. TAKARA K, SAKAEDA T, OKUMURA K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 2006; 12: 273-286.
71. LAVERDIERE C, CHIASSON S, COSTEA I, MOGHRABI A, KRAJINOVIC M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832-3834.
72. BOSSON G. Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell. Br J Biomed Sci 2003; 60: 117-129.
73. MATTANO LA JR, SATHER HN, TRIGG ME et al. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 2000; 18: 3262-3272.
74. MLADOSIEVICOVA B, KAISEROVA E, FOLTINOVA A. Possibility of late consequences of anticancer treatment in childhood. SAP 2007, ISBN 80-8095-004-0 (in press).
75. UITTERLINDEN AG, RALSTON SH, BRANDI ML et al. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level metaanalysis. Ann Intern Med 2006 Aug 15; 145 (4): 255-264. (Pubitemid 46768609)
76. RELLING MV, YANG W, DAS S et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22 (11): 3930-3936.
77. SALONGA D, DANENBERG KD, JOHNSON M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000 Apr; 6(4): 1322-1327.
78. KAGER L, CHEOK M, YANG W et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115: 110-117.
79. STAVROULAKIS GA, MAKRIS TK, KRESPI PG et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drug Ther 2000; 14: 427-432.
80. ISRAEL E, DRAZEN JM, LIGGETT SB et al. Effect of polymorphisms of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124: 183-186.
81. ARRANZ MJ, MUNRO J, BIRKETT J et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615-1616.
82. BERNADIČ M., KULICHOVÁ M.: Problems of pain medicine in pregradual medical and nursing teaching. Reumatológia 2002; 16: 199-200 (in Slovak).
83. HERRINGTON DM, HOWARD TD, HAWKINS GA et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346: 967-974.
84. EVANS WE, McLEOD HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549. (Pubitemid 36159890)